U.S. Inhalable Biologics Market Size & Outlook, 2025-2030
Related Markets
U.S. inhalable biologics market highlights
- The U.S. inhalable biologics market generated a revenue of USD 1,323.1 million in 2024 and is expected to reach USD 3,446.1 million by 2030.
- The U.S. market is expected to grow at a CAGR of 17.3% from 2025 to 2030.
- In terms of segment, peptides and proteins was the largest revenue generating type in 2024.
- RNAi-based Therapeutics is the most lucrative type segment registering the fastest growth during the forecast period.
Inhalable biologics market data book summary
| Market revenue in 2024 | USD 1,323.1 million |
| Market revenue in 2030 | USD 3,446.1 million |
| Growth rate | 17.3% (CAGR from 2025 to 2030) |
| Largest segment | Peptides and proteins |
| Fastest growing segment | RNAi-based Therapeutics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Peptides and Proteins, Vaccines, Monoclonal Antibodies, RNAi-based Therapeutics |
| Key market players worldwide | Kamada, MannKind, Ab Initio, Ocugen, CanSino Biologics Inc Class H, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.9% of the global inhalable biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. inhalable biologics market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 65.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inhalable Biologics Market Scope
Inhalable Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Ocugen | View profile | 51-100 | Malvern, Pennsylvania, United States, North America | http://ocugen.com |
| Ab Initio | View profile | 501-1000 | Lexington, Massachusetts, United States, North America | http://www.abinitio.com |
| MannKind | View profile | 501-1000 | Valencia, California, United States, North America | http://mannkindcorp.com |
| Kamada | View profile | 101-250 | Ness Ziona, HaMerkaz, Israel, Asia | http://kamada.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
U.S. inhalable biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalable biologics market will help companies and investors design strategic landscapes.
Peptides and proteins was the largest segment with a revenue share of 34.9% in 2024. Horizon Databook has segmented the U.S. inhalable biologics market based on peptides and proteins, vaccines, monoclonal antibodies, rnai-based therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. leads the North America Inhalable Biologics market, propelled by substantial biopharma investments, high R&D expenditure, and early regulatory approvals. Rising usage of inhalable biologics for oncology, diabetes, and respiratory diseases is accelerating market growth.
Innovations in peptide and protein-based inhalable, coupled with increasing utilization of nebulizers and soft mist inhalers, are improving drug delivery efficiency. Hospital pharmacies remain the primary distribution channel, with retail pharmacies expanding their presence.
Reasons to subscribe to U.S. inhalable biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. inhalable biologics market databook
-
Our clientele includes a mix of inhalable biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. inhalable biologics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. inhalable biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. inhalable biologics market size, by application, 2018-2030 (US$M)
U.S. Inhalable Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
